AskBio’s gene therapy shows promising 12-month results for heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated